Slingshot members are tracking this event:
Theravance Biopharma (TBPH) announces new developmental partnership with Celgene (CELG) for TD-6450, its multivalent NS5A inhibitor
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Oct 28, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2a, Phase 2 Clinical Trial, Td-6450, Hepatitis C, Partnership